Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence

David Dum1,3, Tjark L.C. Henke1,3, Tim Mandelkow1, Cheng Yang1, Elena Bady1, Jonas B. Raedler1,2, Ronald Simon1,2,3, Guido Sauter1, Maximilian Lennartz1, Franziska Büscheck1, Andreas M. Luebke1, Anne Menz1, Andrea Hinsch1, Doris Hönon1, Christoph Fraune1, Katharina Möller1, Patrick Lebok1, Ria Uhlig1, Christian Bernreuther1, Frank Jacobsen1, Till S. Clauditz1, Waldemar Wilczak1, Sarah Minner1, Eike Burandt1, Stefan Steurer1 and Niclas C. Blessin1

© The Author(s) 2022

INTRODUCTION

CTLA-4 (cytotoxic T-lymphocyte-associated protein 4, CD152) is an inhibitory immune checkpoint receptor and a negative regulator of anti-tumor T-cell function. This study is aimed for a comparative analysis of CTLA-4+ cells between different tumor entities. To quantify CTLA-4+ cells, 4582 tumor samples from 90 different tumor entities as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry in a tissue microarray format. Two different antibody clones (MSVA-152R and CAL49) were validated and quantified using a deep learning framework for automated exclusion of unspecific immunostaining. Comparing both CTLA-4 antibodies revealed a clone dependent unspecific staining pattern in adrenal cortical adenoma (63%) for MSVA-152R and in pheochromocytoma (67%) as well as hepatocellular carcinoma (36%) for CAL49. After automated exclusion of non-specific staining reaction (3.6%), a strong correlation was observed for the densities of CTLA-4+ lymphocytes obtained by both antibodies ($r = 0.87; p < 0.0001$). A high CTLA-4+ cell density was linked to low pT category ($p < 0.0001$), absent lymph node metastases ($p = 0.0354$), and PD-L1 expression in tumor cells or inflammatory cells ($p < 0.0001$ each). A high CTLA-4/CD3-ratio was linked to absent lymph node metastases ($p = 0.0295$) and to PD-L1 positivity on immune cells ($p = 0.0026$). Marked differences exist in the number of CTLA-4+ lymphocytes between tumors. Analyzing two independent antibodies by a deep learning framework can facilitate automated quantification of immunohistochemically analyzed target proteins such as CTLA-4.

Laboratory Investigation (2022) 102:650–657; https://doi.org/10.1038/s41374-022-00728-4

CTLA-4 is an inhibitory immune checkpoint receptor and a negative regulator of anti-tumor T-cell function. This study is aimed for a comparative analysis of CTLA-4+ cells between different tumor entities. To quantify CTLA-4+ cells, 4582 tumor samples from 90 different tumor entities as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry in a tissue microarray format. Two different antibody clones (MSVA-152R and CAL49) were validated and quantified using a deep learning framework for automated exclusion of unspecific immunostaining. Comparing both CTLA-4 antibodies revealed a clone dependent unspecific staining pattern in adrenal cortical adenoma (63%) for MSVA-152R and in pheochromocytoma (67%) as well as hepatocellular carcinoma (36%) for CAL49. After automated exclusion of non-specific staining reaction (3.6%), a strong correlation was observed for the densities of CTLA-4+ lymphocytes obtained by both antibodies ($r = 0.87; p < 0.0001$). A high CTLA-4+ cell density was linked to low pT category ($p < 0.0001$), absent lymph node metastases ($p = 0.0354$), and PD-L1 expression in tumor cells or inflammatory cells ($p < 0.0001$ each). A high CTLA-4/CD3-ratio was linked to absent lymph node metastases ($p = 0.0295$) and to PD-L1 positivity on immune cells ($p = 0.0026$). Marked differences exist in the number of CTLA-4+ lymphocytes between tumors. Analyzing two independent antibodies by a deep learning framework can facilitate automated quantification of immunohistochemically analyzed target proteins such as CTLA-4.

Laboratory Investigation (2022) 102:650–657; https://doi.org/10.1038/s41374-022-00728-4

INTRODUCTION

CTLA-4 (cytotoxic T-lymphocyte-associated protein 4, CD152) is an important inhibitory immune checkpoint receptor. It is expressed on various subtypes of T-lymphocytes including CD4+ and CD8+ T-cells as well as regulatory T-cells1. CTLA-4 can compete with its stimulating counterpart CD28 for ligand binding to CD80 and CD862,3. CD28 co-stimulation is required for T-cell activation, whereas CTLA-4 inhibits T-cell response by opposing the actions of CD28-mediated co-stimulation2,4. Even though CTLA-4 is also expressed on activated CD8+ cytotoxic T-cells, the major physiologic role of CTLA-4 appears to be through down-modulation of non-regulatory T-cell activity and supportively enhancement of regulatory T-cell suppressive activity5–9. The CTLA-4 pathway is a commonly targeted pathway in cancer immunotherapy. For example, the CTLA-4 inhibitor Ipilimumab alone or in combined therapy has been approved for the treatment of advanced malignant melanoma, renal cell and microsatellite instability-high colorectal cancer by the Food and Drug Administration (FDA)5.

Given the pivotal role of CTLA-4 as a successfully used drug target, the prevalence and topographic distribution of CTLA-4+ lymphocytes and lymphocyte subclasses is of interest. Most studies analyzing CTLA-4 in cancer have employed flow cytometry or RNA based methods1,4. Because these techniques are best applicable to unfixed tissues which is unavailable from most tumors in routine praxis, studies on CTLA-4 in cancer mostly involved limited numbers of samples from frequently occurring tumors such as malignant melanoma ($n = 56–470$)9, breast ($n = 928–1217$)10, colorectal ($n = 439–1003$)10–12 and renal cell cancers ($n = 813–928$)10,12,13. Studies on less common tumor entities and larger patient cohorts require the use of routinely processed formalin fixed tissues but were so far hindered by a relative lack of CTLA-4 antibodies suitable for immunohistochemistry (IHC). Antibodies with documented specificity on unprocessed native target protein often show disappointing results on formalin fixed tissues14–16. Potential shortcomings include a lack of target protein staining, an unfavorable signal-to-noise ratio resulting in non-specific background staining, and antibody cross-reactivity resulting in a distinct staining of structures not containing the target protein14,15.

In order to determine the prevalence of CTLA-4+ lymphocytes in a broad range of different tumor entities, a set of preexisting...
Fraction of non-specific staining detected by an AI trained for non-specific staining

Fig. 1 Fraction of non-specific staining detected by an AI framework trained for non-specific staining. The mean fraction of non-specific stained cells is shown for both CTLA-4 antibody clones MSVA-152R (black) and CAL49 (grey). Error bars indicate standard deviations.

MATERIALS AND METHODS

Tissue microarrays (TMAs)

Our normal tissue TMA was composed of 8 samples from 8 different donors for each of the 76 different normal tissue types (608 samples on one slide). The cancer TMAs contained a total of 5706 primary tumors from 134 tumor samples from 90 types and subtypes as well as 76 different normal tissue categories. To compensate for possible shortcomings of CTLA-4 immunohistochemistry, two different CTLA-4 antibodies were used in combination with an artificial intelligence approach for automated discrimination of true from aberrant antibody staining.

Immunohistochemistry (IHC)

Freshly cut 4-µm TMA sections were immunostained on one day and in one experiment. Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in a pH 7.8 buffer. Primary antibody specific for CTLA-4 (rabbit recombinant, clone MSVA-152R, Cat#: 3451–152 R, MS Validated Antibodies GmbH, Hamburg, Germany, 1:50 and rabbit recombinant, clone CAL49, Cat#: ab237712, Abcam, Cambridge, USA, 1:100) were applied at 37 °C for 60 min. Bound antibody was then visualized using the EnVision Kit (Agilent DAKO, Santa Clara, USA) according to the manufacturer's directions.

For multiplex fluorescence IHC a freshly cut 4-µm healthy human tonsil was used. The experimental procedure was performed according to the manufacturer's instructions (AKOYA). Slides were initially boiled in an autoclave (30 min at 100–120 °C in pH9 buffer) for antigen retrieval. The antibody panel consisted of a CD3 antibody for T-cell detection (rabbit polyclonal, Cat#: IRS03, Agilent DAKO, Santa Clara, USA, undiluted), MSVA-152R, and CAL49 for CTLA-4 detection. The OPAL dye kit (Cat#: NEL811001KT, AKOYA Biosciences, Menlo Park, California, United States) was used to detect the primary antibodies CD3 (OPAL 520), MSVA-152R (OPAL 570), and CAL49 (OPAL 690). These were combined with diamidino-2-phenylindole (DAPI) staining. One cycle of antibody staining included peroxidase blocking, application of the primary antibody, detection with a secondary HRP-conjugated antibody, fluorescence dye detection, and removal of the bound antibodies by microwave treatment (5 min at 100 °C and 5 min at a mean temperature of 93 °C). This cycle was repeated two times for the remaining antibodies. Slides were subsequently counterstained with DAPI and mounted in an antifade solution. To measure the co-expression of both CTLA-4 antibody clones in human tonsil (Fig. S1A, B) the CTLA-4 density and expression level were analyzed: Correlation analysis of the CTLA-4 expression level confirmed a high degree of co-expression ($r = 0.81$, $p < 0.0001$; Fig. 1C). In addition, the density of CTLA-4+ cells of both clones was highly concordant in 35 representative areas ($r = 0.85$, $p < 0.0001$, Fig. S1C).

Deep learning-based image analysis

The slides were scanned using Leica’s Aperio AT2 slide scanner. The digital images were analyzed using a two-stage approach combining a convolutional neural network (U-Net) for automated quantification of CTLA-4+ cells (1) and a deep neural network (DeepLab3+) for the detection of non-specific (2) CTLA-4 staining (Fig. 52).
1. The U-Net deep learning system for cell identification was trained and validated as described earlier. In brief, thresholding was used to label cell nuclei and the background of the first 500 patients. After manual correction of this training set the U-Net was trained for 300,000 iterations (∼30 epochs). The trained U-Net was used to analyze/label further 500 patients, which were also manually corrected. A new U-Net was trained based on these two training sets to label the next 500 patients. The process was used to continuously increased the training set until 3306 (75%) TMA spots (from 90 different tumor entities), were successfully labeled, manually corrected, and used for the training of the final U-Net for cell segmentation. Of note, to avoid introducing potential bias by selective manually correction two trained pathologist were relabeling and manually correcting the labels. The threshold for CTLA-4 positivity was visually investigated. The area in square millimeter of each spots was calculated by a pretrained U-Net algorithm.

2. The DeepLab3+ deep learning system for detecting aberrant antibody staining was trained on 75% of cases for every tumor entity to assure a balanced training input. A pathologist identified regions and TMA cores showing non-specific staining so that thresholding could be used to label regions of non-specific staining as well as background. Comparison of the staining pattern from both CTLA-4 clones for the same consecutive TMA spot enabled the identification of false positive antibody staining. Specific CTLA-4

Fig. 2 CTLA-4 immunostaining of normal tissues. The panels show for the antibody MSVA-152R a strong membranous positivity of a subset of lymphocytes in the tonsil (A), a strong cytoplasmatic staining of the adrenal cortex (B) and a cytoplasmic granular staining in a fraction of superficial epithelial cells of the stomach (C) and of renal tubuli (D). For the antibody CAL49, a strong membranous positivity of the same subset of lymphocytes in the tonsil (E), a weak cytoplasmatic staining of the adrenal medulla (F), a strong cytoplasmatic staining superficial epithelial cells of the stomach (G), and an apical membranous staining of renal tubuli (H) is seen. The images (A–D) and (E–H) are from consecutive tissue sections and taken at 20x magnification.

Fig. 3 Distinct target staining and non-overlapping cross-reactivities of two CTLA-4 antibodies. The panels show for the antibody MSVA-152R a strong staining of a subset of lymphocytes in a Hodgkin’s lymphoma (A), a strong cytoplasmatic staining of an adrenocortical adenoma (B) absence of staining in a pheochromocytoma (C), and a staining of few lymphocytes in a hepatocellular carcinoma (D). For the antibody CAL49, an equally strong staining of the identical subset of lymphocytes in a Hodgkin’s lymphoma is seen (E), while staining is lacking in an adrenocortical adenoma (F), and a cytoplasmic staining occurs in a pheochromocytoma (G) and a hepatocellular carcinoma (H). The images (A–D) and (E–H) are from consecutive tissue sections and taken at 20x magnification.
staining was labeled as background. The mean fraction of non-specific stained cells per tumor entity is shown in Fig. 1. Tumor samples with 5% or more cells with non-specific staining were identified as a case driven by false positive staining and excluded from further analysis (Fig. S3). Thus, the mean CTLA-4 density (cells/mm²) of both antibodies was based on TMA cores showing 4% or less non-specific CTLA-4 staining. The performance of both deep learning systems was evaluated by calculating the area under (AUC) receiver operating characteristics (ROC) using the remaining (25%) of patients as a validation set (Fig. S3). Python version 3.8 and the Visiopharm software package (Hoersholm, Denmark) were used to label, train, and validate the deep learning systems.

Statistical analysis
Statistical calculations were performed with R version 3.6.1 (The R foundation) and JMP Pro 15 software package (SAS Institute Inc., NC, USA). Contingency tables and the Chi-square test were used to search for associations between the density of CTLA-4 and tumor phenotype. All p values were two-sided, and p < 0.05 were considered as significant.

RESULTS
CTLA-4 in normal tissues
Using both antibodies, a strong and distinct, predominantly membranous CTLA-4 immunostaining was seen in a subset of T-lymphocytes. Both antibodies also stained thyroidal colloid. In addition, for MSVA-152R, an intense granular cytoplasmic staining could be seen in adrenocortical cells and decidua cells while a less conspicuous granular staining could be observed in the apical cytoplasm of tall columnar cells of the epididymis, pancreatic acinar cells, hepatocytes, and gastrointestinal surface epithelium cells. For CAL49 a strong cytoplasmic staining was seen in gastric surface epithelial cells and sebaceous glands while a weak cytoplasmic staining was seen in medullary cells of the thyroid and a weak to moderate staining of apical membranes in selected renal tubuli. All these stainings which were distinct when applying one antibody but absent for the other antibody were considered antibody-specific cross-reactivities. Although thyroidal colloid was stained by both antibodies, this staining was also rather considered cross-reactive because the function of CTLA-4 is not consistent with a role as a thyroidal colloid component. Representative images are shown in Fig. 2.

CTLA-4 antibody validation in tumor tissues
A total of 9405 images from 90 different tumor entities were used to train and validate a deep learning-based approach for detecting non-specific staining (Fig. S2). Our approach identified a high fraction of non-specific staining for MSVA-152R in adrenal cortical adenoma (58%) and for CAL49 in pheochromocytoma (66%) as well as hepatocellular carcinoma (35%, Fig. 1). Non-specific staining for both antibodies was found in 1% to 8% of cells in malignant melanomas, adrenocortical carcinomas, renal and thyroidal tumors. Representative tumor images are shown in Fig. 3. After automated exclusion of perceived non-specific staining reaction in 126 cases (2.7%) of the 4723 cases stained with MSVA-152R and in 213 (4.5%) of the 4682 cases stained with CAL49, a strong correlation was observed for the densities of CTLA-4+ cells obtained by our two antibodies (r = 0.93; p < 0.0001; Fig. S4). For all further analyses, the average densities of CTLA-4+ cells obtained by both antibodies were used for each patient except for tumor samples with >5% of non-specific staining. In these cases, only the data from the antibody with specific staining was utilized.

CTLA-4 in tumor tissues
A total of 4582 different patients from 90 different tumor entities — after exclusion of 339 (3.6%) of 9405 cases — were analyzed in this study. The mean density of CTLA-4+ cells was 674 ± 1482 cells/mm² and ranged from 71 ± 175 cells/mm² in leiomyoma to 5916 ± 3826 cells/mm² in Hodgkin’s lymphoma (Fig. 4; Table S1). A comparison of the densities of CTLA-4+ cells in different tumor
categories identified highest values in lymphomas (3642 ± 3207 cells/mm²), biphasic (609 ± 1057 cells/mm²) as well as germ cell tumors (401 ± 468 cells/mm²) and the lowest in mesothelial (281 ± 320 cells/mm²) as well as mesenchymal neoplasms (145 ± 268 cells/mm²; Table 1). Within epithelial tumors, the density of CTLA-4+ cells was higher in squamous cell (421 ± 469 cells/mm²) and urothelial carcinomas (418 ± 347 cells/mm²) than in adenocarcinomas (268 ± 375 cells/mm²) and renal cell neoplasms (256 ± 269 cells/mm²; Table 1). A comparison with histologic parameters and PD-L1 status revealed significantly higher rates of CTLA-4+ cells in tumors with low pT category (p < 0.0001), absent lymph node metastases (p = 0.003), and PD-L1 expression in tumor cells or inflammatory cells (p < 0.0001 each; Table 2). Similar associations were also seen within the more homogeneous subgroups of adenocarcinomas and squamous cell carcinomas (data not shown). Across 908 squamous cell carcinomas, a high density of CTLA-4+ cells was linked to a positive HPV status (p = 0.0130; Table 2). Unequivocal CTLA-4 immunostaining of tumor cells was not seen in our patients.

**DISCUSSION**

The data from this study demonstrate the feasibility of a reliable and precise high-throughput quantification of lymphocyte sub-populations by employing an AI supported multiple antibody approach. Two different CTLA-4 antibodies were used for this study because the use of multiple independent antibodies is the only practically feasible approach for validating lymphocyte marker antibodies for immunohistochemistry on formalin fixed tissues.
Although the International Working Group for Antibody Validation (IWGAV) has proposed that antibody validation for immunohistochemistry could alternatively include a comparison of the IHC findings with expression data obtained by another independent method, this approach is not practical for immune cell markers due to the widespread distribution of immune cells across virtually all tissues. That both applied antibodies identified almost identical subsets of lymphocytes in multicolor analyses demonstrates, provides strong evidence for both antibodies recognizing CTLA-4 subsets of lymphocytes in only few examples, we had recently observed non-specific antibody staining. However, a major hurdle in developing an AI approach to improve the detection of non-specific antibody staining was the fact that in most tumor entities the staining quality of both antibodies was complementary to each other (i.e., at least one of the antibody clones showed a specific staining). The CAL49 staining observed in stomach and kidney epithelium as well as the MSVA-152R staining in adrenal gland, decidua cells and other epithelial cells are thus considered antibody cross-reactivities. Cross-reactivities of diagnostically used antibodies are not uncommonly found if an extensive normal tissue screening is executed. For example, we had recently observed non-specific antibody staining patterns in different normal tissue categories also indeed identified multiple tissue structures that were significantly stained by one antibody but not by the other. While a staining of the target protein can be expected to occur with every suitable antibody it is likely that cross-reactivities are more antibody specific and therefore will involve non-overlapping tissues and cell types. The CAL49 staining seen in stomach and kidney epithelium as well as the MSVA-152R staining in adrenal gland, decidua cells and other epithelial cells are thus considered antibody cross-reactivities. Cross-reactivities of diagnostically used antibodies are not uncommonly found if an extensive normal tissue screening is executed. For example, we had recently observed non-specific antibody staining of smooth muscle for the PLAP antibody clone 8A927, spermatocytes of the testis for the DOG1 clone SP3128, and of corpus luteum of the ovary, adrenal cortical cells, decidua cells for the SATB2 clone 1003. The thorough analysis of >4582 tumors from 90 different tumor types demonstrated in this study, that the cross-reactivities detected for our two CTLA-4 antibodies hindered the quantification of CTLA-4⁺ lymphocytes in only few tumor entities. Because the artefact prone tumor entities were antibody-specific and did not overlap for our antibodies, the use of just two antibodies enabled a successful analysis of the entire tumor set although a few individual tumors such as heavily pigmented melanoma cases remained uninformative for both antibodies. It is of note, that several earlier IHC studies had described CTLA-4 to occur in tumor cells of malignant melanoma, breast cancer, and esophageal carcinomas. Given the complete lack of confirmed tumor cell staining in the 4582 cancers of our study, it appears possible that these earlier reports were based on non-specific antibody binding to tumor cells.

The fact that the analysis of more than 4000 tumor samples from 90 different tumor entities was executed using the same deep-learning algorithm for both antibodies was a major strongpoint of this study and enabled a fully reproducible evaluation of non-specific staining for multiple antibodies. Thus, the Artificial Intelligence (AI) framework for the detection of non-specific staining reaction was trained on immunostaining of both antibodies—in an equal proportion—to ensure a good performance for both antibody clones. To cover such a wide range of different staining patterns of multiple antibodies across various tumor entities, the AI framework was based on an AI for cell segmentation and the pivotal AI for detecting non-specific antibody staining. However, a major hurdle in developing an AI specific for non-specific staining was to achieve a great diversity of non-specific staining patterns as well as specific lymphocytic staining patterns in the training set. Here, we took advantage of the fact that in most tumor entities the staining quality of both antibodies was complementary to each other (i.e., at least one of the antibody clones showed a specific immunostaining), which dramatically increased the accuracy of our AI. In addition, another advantage of CTLA-4 was the fundamental differences in the shape of CTLA-4⁺ lymphocytes and non-specific staining. Therefore, the AI approach described in this study can be particularly effective in case of lymphocyte markers. For the future, the

### Table 2. Association between the CTLA-4⁺ cell density (cells/mm²) as well as the CTLA4/CD3-ratio and clinicopathological parameters.

| Characteristic | Patient number (%) | CTLA4⁺ cell density | p value | Patient number (%) | CTLA4/CD3-ratio | p value |
|---------------|--------------------|----------------------|---------|--------------------|-----------------|---------|
| Pathological tumor stage | | | | | | |
| 4582 | | | | | | |
| pT1 | 763 (16.7%) | 410 (±570) | <0.0001 | 673 (±1482) median: 214 | 410 (±570) | <0.0001 |
| pT2 | 746 (16.3%) | 350 (±467) | 0.1846 | 714 (±46) | 15 (±30) | 0.0026 |
| pT3 | 839 (18.3%) | 273 (±364) | 0.0031 | 710 (±65) | 16 (±39) | 0.0354 |
| pT4 | 341 (7.4%) | 306 (±345) | 0.0001 | 328 (7.6%) | 15 (±30) | 0.0001 |
| Missing data | 1893 (41.3%) | - | | 1800 (41.9%) | - | |
| Pathological nodal stage | | | | | | |
| 4582 | | | | | | |
| pN− | 839 (18.3%) | 373 (±491) | 0.0001 | 794 (18.5%) | 21 (±55) | 0.0001 |
| pN+ | 1003 (21.9%) | 312 (±398) | 0.0001 | 962 (22.4%) | 16 (±37) | 0.0001 |
| Missing data | 2740 (59.8%) | | | 2536 (59.1%) | | |
| PD-L1 on tumor cells | | | | | | |
| 4582 | | | | | | |
| Negative | 2583 (56.4%) | 373 (±1382) | <0.0001 | 2498 (58.2%) | 16 (±49) | 0.0026 |
| Positive | 662 (14.4%) | 920 (±1744) | 0.0001 | 605 (14.1%) | 23 (±64) | 0.0101 |
| Missing data | 1337 (29.2%) | | | 1189 (27.7%) | | |
| PD-L1 on immune cells | | | | | | |
| 4582 | | | | | | |
| Negative | 2063 (45.0%) | 310 (±534) | <0.0001 | 2068 (48.2%) | 19 (±59) | 0.0001 |
| Positive | 1371 (29.9%) | 1233 (±2059) | 0.0001 | 1231 (28.7%) | 16 (±45) | 0.0001 |
| Missing data | 1148 (25.1%) | | | 993 (23.1%) | | |
| HPV | | | | | | |
| 4582 | | | | | | |
| Negative | 326 (7.1%) | 393 (±392) | 0.0130 | 291 (6.8%) | 25 (±56) | 0.0920 |
| Positive | 243 (5.3%) | 489 (±524) | 0.0130 | 221 (5.2%) | 25 (±40) | 0.0130 |
| Missing data | 4013 (87.6%) | | | 3780 (88.0%) | | |
purpose of this AI approach is—similar to other AI based decision support systems in pathology—to assist the pathologist by excluding >90% of unimportant tumor samples and pointing out the TMA cores of interest (i.e., with potential non-specific staining). Taken together, integrating an AI framework in the process of antibody validation might result in an efficient semi-automated workflow for quality assessment of new antibody clones.

Several data generated from our tumor cohort suggest a possible biological relevance of CTLA-4+ lymphocytes. Although the prognostic role of CTLA-4 has been reported contradictory\(^9\), the fact that the density of CTLA-4+ lymphocytes varied between tumor types as well as between individual tumors and that the CTLA-4 density was lower in tumors of advanced clinico-pathological parameters was expected because similar findings had been observed for an inflamed immune phenotype\(^{16, 19}\), CD3\(^+\), CD8\(^+\), and CD4\(^+\) lymphocytes as well as for PD-L1+ immune cells\(^{15, 21}\) or CD112R+ lymphocyte subsets\(^{22}\). For the same reason, the significant link between a high number of CTLA-4+ cells and PD-L1 expression in tumor cells or tumor associated inflammatory cells is also consistent with the literature\(^9\). Despite the expected general link between high absolute numbers of CTLA-4+ cells and favorable tumor features, there were also some associations between a high CTLA-4/CD3-ratio and favorable tumor features. The latter finding would clearly fit with the concept that immune checkpoint receptors—such as CTLA-4—are upregulated in T-cell accumulations in the tumor micro-environment, so that a high immune checkpoint expression functions as a surrogate for a high number of T-cell accumulations (i.e., a high T-cell density, an inflamed immune phenotype)\(^{21, 43–45}\). Given that the CD3 density was quantified in an earlier study on non-consecutive slides, it is possible that some associations with clinico-pathological parameters might be underrated in this study. Several other studies have also suggested that a high expression of CTLA-4+ on T-cells is linked to a favorable disease outcome or tumor features in 289 squamous cell lung cancer\(^6\), 162 testicular germ cell tumors\(^9\), 130 breast cancers\(^8\), 45 mesothelioma patients\(^{48}\), and 39 B-cell chronic lymphocytic leukemia\(^{49}\).

In summary, CTLA-4+ cells could be rapidly and precisely quantitated in this study despite inherent limitations of available CTLA-4 antibodies. The use of two independent antibodies enabled our AI to automatically distinguish “true” from “false” immunostaining and enabled the identification of potentially relevant biologically data such as a link between a low ratio of CTLA-4/CD3 and PD-L1+ immune cells. Further investigations on the role of CTLA-4+ lymphocyte subsets by multiplex fluorescence IHC will most likely benefit from using similar approaches as described here.

**DATA AVAILABILITY**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**REFERENCES**

1. Chan, D. V. et al. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFTA1 and inhibition of CD4+ proliferation. *Genes Immun.* 15, 25–32 (2014).
2. Sansom, D. M. CD28, CTLA-4 and their ligands: who does what and to whom? *Immunology* 101, 169–177 (2000).
3. Rawsheshanran, B., Halliday, N. & Sansom, D. M. CTLA-4: a moving target in immunotherapy. *Blood* 131, 58–67 (2018).
4. Lindsten, T. et al. Characterization of CTLA-4 structure and expression on human T cells. *J. Immunol.* 151, 3489–3499 (1993).
5. Friedline, R. H. et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. *J. Exp. Med.* 206, 421–434 (2009).
6. Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. *Science* 322, 271–275 (2008).
7. Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R. & Chandra, A. B. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. *Cancers (Basel)* 12, 738–757 (2020).
8. Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. *Sci. Transl. Med.* 9, eaah3560 (2017).
9. Golitz, D. et al. CTLA4 methylation predicts response to anti-PD1 and anti-CTLA-4 immunotherapy in melanoma patients. *JCI Insight* 3, e96793 (2018).
10. Zhang, P. et al. Mechanism- and immune landscape-based ranking of therapeutic responsiveness of 22 major human cancers to next generation Anti-CTLA-4 antibodies. *Cancers (Basel)* 12, 284–303 (2020).
11. Zou, C. et al. CTLA4 tagging polymorphisms and risk of colorectal cancer: a case-control study involving 2,306 subjects. *Onco. Targets Ther.* 11, 4609–4619 (2018).
12. Liu, J. N. et al. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study. *Front. Immunol.* 11, 2048 (2020).
13. Cesana, G. C. et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. *J. Clin. Oncol.* 24, 1169–1177 (2006).
14. Hewitt, S. M., Baskin, D. G., Frevert, C. W., Stahl, W. L. & Rosa-Molina, E. Controls for immunohistochemistry: the Histochemical Society’s standards of practice for validation of immunohistochemical assays. *J. Histochem. Cytochem.* 62, 693–697 (2014).
15. Buchwalow, I., Samolovova, V., Boecker, W. & Tiemann, M. Non-specific binding of antibodies in immunohistochemistry: fallacies and facts. *Sci. Rep.* 1, 28 (2011).
16. Saper, C. B. A guide to the perplexed on the specificity of antibodies. *J. Histochem. Cytochem.* 57, 1–5 (2009).
17. Bady, E. et al. BLEACH&STAIN 15 marker multiplexed imaging in 3098 human tumors revealed six major PD-L1 driven immune phenotypes with distinct spatial orchestration. *Nat. Methods* (submitted) (2021).
18. Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat. Med.* 4, 844–847 (1998).
19. Mirlacher, M. & Simon, R. Recipient block TMA technique. *Methods Mol. Biol.* 664, 37–44 (2010).
20. Blesson, N. C. et al. Automated Ki67-LI assessment in prostate cancer using artificial intelligence in multiplex fluorescence immunohistochemistry *European Urology* (submitted, temporary download here: https://mega.nz/#!yWrdJZi7v97...7wmcCSJJgBodYQUA) (2021).
21. Blesson, N. C. et al. Deep profiling revealed an upregulation of CD112R in human cancer. *Cancer Immunol. Res.* (submitted) (2021).
22. Foundation, P. S. Python Language Reference, *Available at http://www.python.org*. (2021).
23. Tippmann, S. Programming tools: adventures with *R. Nature* 517, 109–110 (2015).
24. R-Core-Team. R: A language and environment for statistical computing. *R Foundation for Statistical Computing. Vienna, Austria. URL: https://www.R-project.org/* (2021).
25. JMP®, V. SAS Institute Inc., Cary, NC, *https://wwwjmp.com* 1989–2019.
26. Uhlen, M. et al. A proposal for validation of antibodies. *Nat. Methods* 13, 823–827 (2016).
27. Reiswiz, V. et al. Pattern of placental alkaline phosphatase (PLAP) expression in human tumors: a tissue microarray study on 12,381 tumors. *J. Pathol. Clin. Res.* 7, 577–589 (2021).
28. Jansen, K. et al. DOG1 expression is common in human tumors: a tissue microarray study on more than 15,000 tissue samples. *Pathol. Res. Pract.* 228, 153663 (2021).
29. Dum, D., Kromm, D., …, Clautitz, S. T. & Krech, T. SATB2 expression in human tumors: a tissue microarray study on more than 15,000 tumors. (2022). (In press).
30. Ghorabi, Z., Jorda, M., Ganjei, P. & Nadji, M. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. *Appl. Immunohistochem. Mol. Morphol.* 11, 330–333 (2003).
31. Laurent, S. et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. *J. Transl. Med.* 11, 108 (2013).
32. Yoon, C. et al. CT18 immunofluorescence staining in immunohistochemistry: implications for prognosis. *Cancer Immunol. Immunother.* 64, 853–860 (2015).
33. Zhang, X. F. et al. Ct170 T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. *Cancer Immunol. Immunother.* 64, 26670–26679 (2016).
34. Campanella, G. et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. *Nat. Med.* 25, 1301–1309 (2019).
35. Hu, P. et al. The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis. *Sci. Rep.* 7, 42913 (2017).
36. Blesson, N. C. et al. Prognostic role of proliferating CD68(+) cytotoxic Tcells in human cancers. *Cell Oncol.* (Dordr). *https://doi.org/10.1007/s13402-021-00604-1* (2021).
ACKNOWLEDGEMENTS

We thank Julia Ebner, Inge Brandt, Melanie Witt, Maren Eisenberg and Sünje Seekamp for excellent technical assistance.

AUTHOR CONTRIBUTIONS

Conception and design: D.D., T.H., R.S., G.S., N.B. Development of methodology: D.D., T.H., R.S., G.S., N.B. Acquisition of data: D.D., T.H., T.M., C.Y., E.B., J.R. Analysis and interpretation of data: D.D., T.H., T.M., C.Y., E.B., J.R., R.S., G.S., N.B. Writing, review, and/or revision of the manuscript: D.D., T.H., R.S., G.S., N.B. Administrative, technical, or material support: D.D., T.H., T.M., C.Y., E.B., J.R., M.L., F.B., A.L., A.M., A.H., D.H., S.W., C.F., K.M., P.L., R.U., C.B., F.J., T.C., W.W., S.M., E.Bu, S.S., N.B. Study supervision: G.S., R.S., and N.B. All authors read and approved the final manuscript.

FUNDING

Open Access funding enabled and organized by Projekt DEAL.

COMPETING INTERESTS

All authors except one (GS) declare no conflict of interest. The CTLA-4 antibody clone MSVA-152R was provided from MS Validated Antibodies GmbH (owned by a family member of GS).

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Usage of archived tissues has been approved by local laws (HmgKhG §12) and the local ethics committee (Ethics commission Hamburg, WF-049/09). All work has been carried out in compliance with the Helsinki Declaration.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41374-022-00728-4.

Correspondence and requests for materials should be addressed to Ronald Simon.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022